RWS launches new linguistic validation service for clinical trials

RWS, a global AI solutions company, has introduced a new tech-enabled eCOA translation and linguistic validation service. The service is designed to help pharmaceutical companies, clinical research organizations (CROs), and eCOA providers reduce delays in global clinical trials.

The new offering consolidates critical eCOA trial services under a single program team. This integrated model brings together COA licensing, source validation, multilingual translation, eCOA migration, intelligent workflows, rater training, and dedicated program management. The goal is to provide end-to-end governance and a single point of accountability across the entire COA lifecycle.

Global clinical trials depend on precise timing, and language is often a significant bottleneck. Many organizations still manage licensing, translation, and migration across multiple vendors and systems, leading to handoffs, blurred accountability, and compounded delays that can impact study startup and regulatory submissions. RWS's redesigned service model focuses on dedicated program management and intelligent workflows, with a single leadership team overseeing planning, execution, and risk management. The company is also incorporating AI-powered tools and automation to enhance efficiency and quality.

By eliminating traditional service silos, RWS aims to provide streamlined communication, consistent governance, and simplified vendor management. This approach helps sponsors reduce complexity, protect endpoint quality, and accelerate the execution of global studies.